标题
Molecular profiling of gliomas: potential therapeutic implications
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 15, Issue 8, Pages 955-962
出版商
Informa UK Limited
发表日期
2015-06-29
DOI
10.1586/14737140.2015.1062368
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
- (2015) Michael Weller et al. ACTA NEUROPATHOLOGICA
- Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
- (2015) Yuchen Jiao et al. Oncotarget
- 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
- (2015) Alexandra Borodovsky et al. Oncotarget
- Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
- (2015) Sevin Turcan et al. Oncotarget
- Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells
- (2014) Mark Barszczyk et al. ACTA NEUROPATHOLOGICA
- Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
- (2014) M Holderfield et al. BRITISH JOURNAL OF CANCER
- The future of antiangiogenic treatment in glioblastoma
- (2014) Oliver L. Chinot et al. CURRENT OPINION IN NEUROLOGY
- Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH
- (2014) J. Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
- (2014) David Neal Franz et al. LANCET ONCOLOGY
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
- (2014) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib
- (2014) A. Idbaih et al. NEUROLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pilomyxoid astrocytoma treated successfully with vemurafenib
- (2014) Mary Skrypek et al. PEDIATRIC BLOOD & CANCER
- EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
- (2014) J. M. Francis et al. Cancer Discovery
- Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
- (2013) Hideyuki Arita et al. ACTA NEUROPATHOLOGICA
- Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
- (2013) Christian Koelsche et al. ACTA NEUROPATHOLOGICA
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Predictive biomarkers in adult gliomas
- (2013) Laure Thomas et al. CURRENT OPINION IN ONCOLOGY
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
- (2013) David T W Jones et al. NATURE GENETICS
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
- (2013) P. J. Killela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
- (2013) A. Sottoriva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
- (2012) Felix Sahm et al. ACTA NEUROPATHOLOGICA
- Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g
- (2012) Véronique Quillien et al. CANCER
- Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951
- (2012) Lale Erdem-Eraslan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution
- (2012) C. Colin et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma
- (2012) Arne Christians et al. PLoS One
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
- (2011) Genevieve Schindler et al. ACTA NEUROPATHOLOGICA
- Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
- (2011) C. Hartmann et al. CLINICAL CANCER RESEARCH
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
- (2011) Jaime Gállego Pérez-Larraya et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
- (2011) Stephen Yip et al. JOURNAL OF PATHOLOGY
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
- (2010) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective
- (2010) Martin J. van den Bent ACTA NEUROPATHOLOGICA
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma
- (2010) Anja E. Eisenhardt et al. INTERNATIONAL JOURNAL OF CANCER
- MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential
- (2010) Judith WM Jeuken et al. JOURNAL OF PATHOLOGY
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
- (2010) C. Houillier et al. NEUROLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duplication of 7q34 in Pediatric Low-Grade Astrocytomas Detected by High-Density Single-Nucleotide Polymorphism-Based Genotype Arrays Results in a NovelBRAFFusion Gene
- (2009) Angela J. Sievert et al. BRAIN PATHOLOGY
- Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours
- (2009) K Jacob et al. BRITISH JOURNAL OF CANCER
- Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402
- (2009) Meihua Wang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
- (2009) Marc Sanson et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma
- (2009) J. Yu et al. NEUROLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas
- (2008) David T.W. Jones et al. CANCER RESEARCH
- BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
- (2008) Stefan Pfister et al. JOURNAL OF CLINICAL INVESTIGATION
- Frequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma
- (2008) Eli E. Bar et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Clinicopathological features and global genomic copy number alterations of pilomyxoid astrocytoma in the hypothalamus/optic pathway: comparative analysis with pilocytic astrocytoma using array-based comparative genomic hybridization
- (2008) Yoon-Kyung Jeon et al. MODERN PATHOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
- (2008) John H. Sampson et al. NEURO-ONCOLOGY
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started